Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Evelo Biosciences Inc (EVLO)

Evelo Biosciences Inc (EVLO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 949
  • Shares Outstanding, K 18,983
  • Annual Sales, $ 0 K
  • Annual Income, $ -114,530 K
  • 60-Month Beta 2.03
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade EVLO with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -13.01
  • Most Recent Earnings $-0.66 on 11/09/23
  • Latest Earnings Date 05/20/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0350 +42.86%
on 04/05/24
0.0690 -27.54%
on 03/25/24
-0.0188 (-27.33%)
since 03/18/24
3-Month
0.0350 +42.86%
on 04/05/24
0.0700 -28.57%
on 02/28/24
-0.0056 (-10.07%)
since 01/18/24
52-Week
0.0280 +78.57%
on 12/15/23
13.9300 -99.64%
on 08/15/23
-3.1680 (-98.45%)
since 04/18/23

Most Recent Stories

More News
Stocks Move Higher Before the Open as Focus Shifts to Fed Meeting Next Week

September S&P 500 futures (ESU23) are up +0.25%, and September Nasdaq 100 E-Mini futures (NQU23) are up +0.36% this morning after three major U.S. benchmark indices closed mixed on Thursday as market participants...

ESU23 : 4,491.72s (-0.32%)
NQU23 : 15,435.20s (-0.28%)
JNJ : 146.24 (+0.34%)
NFLX : 572.97 (-6.16%)
TSLA : 149.58 (-0.23%)
AMAT : 193.72 (-0.31%)
AMD : 152.00 (-1.99%)
AXP : 224.50 (+3.22%)
SLB : 49.84 (-2.16%)
ROP : 530.88 (+0.68%)
SAP.D.DX : 166.740 (-1.41%)
LONN.Z.IX : 503.800 (-1.52%)
Cellarity Strengthens Executive Leadership Team

Cellarity , a life sciences company founded by Flagship Pioneering to transform the way medicines are discovered, announced today the appointments of John Leaman, M.D., M.B.A., as Chief Financial Officer...

IMPL : 0.0400 (-27.27%)
SELB : 0.8812 (-8.00%)
MDGN : 5.57 (+3.15%)
DNLI : 16.59 (-0.06%)
EVLO : 0.0495 (-1.00%)
FHTX : 5.64 (+1.90%)
MRNA : 102.88 (+0.86%)
OMGA : 2.45 (+1.24%)
SANA : 7.74 (+0.13%)
MCRB : 0.5905 (+1.08%)
Forget Bargain Hunting, Buy 4 Stocks With Rising P/E

Tap four stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include James River Group (JRVR), MakeMyTrip Limited (MMYT), Evelo Biosciences (EVLO) and The Kroger Co. (KR)....

KR : 56.00 (+0.77%)
MMYT : 61.50 (+0.46%)
JRVR : 9.23 (+0.22%)
EVLO : 0.0495 (-1.00%)
Flagship Pioneering Unveils Ampersand Biomedicines to Create Highly Effective Medicines That Are Programed to Act Only Where Needed

Flagship Pioneering, the bioplatform innovation company, today unveiled Ampersand Biomedicines, a company creating programmable medicines that are safer, more tolerable, and effective by acting at the...

DNLI : 16.59 (-0.06%)
EVLO : 0.0495 (-1.00%)
FHTX : 5.64 (+1.90%)
MRNA : 102.88 (+0.86%)
OMGA : 2.45 (+1.24%)
SANA : 7.74 (+0.13%)
MCRB : 0.5905 (+1.08%)
After Plunging -40.39% in 4 Weeks, Here's Why the Trend Might Reverse for Evelo Biosciences, Inc. (EVLO)

Evelo Biosciences, Inc. (EVLO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts...

EVLO : 0.0495 (-1.00%)
Charles River and Flagship’s Pioneering Medicines Enter Agreement Leveraging AI-Powered Logica with Aim of Creating Novel Therapies for Unmet Medical Needs

Charles River Laboratories International, Inc. (NYSE: CRL) today announced a multi-program agreement with Pioneering Medicines, a strategic initiative of Flagship Pioneering, that gives Pioneering Medicines...

CRL : 229.97 (+1.06%)
DNLI : 16.59 (-0.06%)
EVLO : 0.0495 (-1.00%)
FHTX : 5.64 (+1.90%)
MRNA : 102.88 (+0.86%)
OMGA : 2.45 (+1.24%)
SANA : 7.74 (+0.13%)
MCRB : 0.5905 (+1.08%)
Down -39.46% in 4 Weeks, Here's Why Evelo Biosciences, Inc. (EVLO) Looks Ripe for a Turnaround

The heavy selling pressure might have exhausted for Evelo Biosciences, Inc. (EVLO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street...

EVLO : 0.0495 (-1.00%)
Horizon Technology Finance Provides Fourth Quarter 2022 Portfolio Update

/PRNewswire/ -- Horizon Technology Finance Corporation (NASDAQ: HRZN) ("HRZN" or the "Company"), a leading specialty finance company that provides capital in...

HRZN : 11.45 (+0.70%)
EVLO : 0.0495 (-1.00%)
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Evelo Biosciences, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors

/PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of...

EVLO : 0.0495 (-1.00%)
Cellarity Announces Close of $121 Million Series C Financing

Cellarity , a life sciences company founded by Flagship Pioneering to transform the way medicines are created, announced today the completion of a $121 million Series C financing, bringing its total funding...

DNLI : 16.59 (-0.06%)
EVLO : 0.0495 (-1.00%)
FHTX : 5.64 (+1.90%)
MRNA : 102.88 (+0.86%)
OMGA : 2.45 (+1.24%)
RUBY : 0.0570 (+2.70%)
SANA : 7.74 (+0.13%)
MCRB : 0.5905 (+1.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Key Turning Points

3rd Resistance Point 0.0500
2nd Resistance Point 0.0500
1st Resistance Point 0.0500
Last Price 0.0495
1st Support Level 0.0500
2nd Support Level 0.0500
3rd Support Level 0.0500

See More

52-Week High 13.9300
Fibonacci 61.8% 8.6194
Fibonacci 50% 6.9790
Fibonacci 38.2% 5.3386
Last Price 0.0495
52-Week Low 0.0280

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar